Advanced Search

    column
    Accelerate the Transformation of Oncology Pharmacists’ Services and Promote the Development of Oncology Pharmacy
    DING Haiying, XIN Wenxiu, TONG Yinghui, FANG Luo, LI Guohui
    2023, 40(12): 1585-1587. DOI: 10.13748/j.cnki.issn1007-7693.20231567
    Abstract PDF
    Research Progress of Pharmacokinetics Studies of Anti-tumor Drugs in Patients with Third Space Fluid
    XU Gaoqi, YANG Dihong, XIN Wenxiu, DING Haiying, ZHU Junfeng, ZHONG Like, HE Chaoneng, FANG Luo
    2023, 40(12): 1596-1602. DOI: 10.13748/j.cnki.issn1007-7693.20231440
    Abstract PDF
    Data Mining and Analysis of Adverse Events for Lutetium Lu 177 Vipivotide Tetraxetan
    JIANG Cheng, YUAN Yong, CHEN Yunwang, JIANG Xin, TANG Zhongzhu
    2023, 40(12): 1603-1608. DOI: 10.13748/j.cnki.issn1007-7693.20230797
    Abstract PDF
    Pharmacoeconomic Evaluation of Abemaciclib in Combination with Fulvestrant for Second-line Treatment of Hormone Receptor-positive Advanced Breast Cancer
    JIA Caifeng, FENG Zhangying, ZHANG Sen, XU Hao, KANG Shuo, LI Sainan, WANG Mingxia
    2023, 40(12): 1609-1614. DOI: 10.13748/j.cnki.issn1007-7693.20222787
    Abstract PDF
    Establishment of Oxaliplatin Evaluation Criteria Based on Weighted TOPSIS Method and Drug Rationality Evaluation
    LIU Hongfeng, FAN Xiuying, ZHANG Yinyin
    2023, 40(12): 1615-1620. DOI: 10.13748/j.cnki.issn1007-7693.20221741
    Abstract PDF
    Systematic Review of Economic Evaluation of Targeted Drugs for Colorectal Cancer Treatment in China
    WANG Kaixuan, LI Shunping, DOU Lei, LIU Shixian, SHI Zhao, WANG Ruixue
    2023, 40(12): 1621-1629. DOI: 10.13748/j.cnki.issn1007-7693.20221372
    Abstract PDF
    Adverse Event Signal Analysis of Three BTK Inhibitors Based on OpenFDA
    XUE Shuyi, YIN Guisen, CUI Xiao, ZHANG Yanhua, ZHANG Guanmin
    2023, 40(12): 1630-1636. DOI: 10.13748/j.cnki.issn1007-7693.20223928
    Abstract PDF
    Cost-effectiveness Analysis of Toripalimab Plus Chemotherapy as First Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
    YAN Xiaoyu, LU Yun, CHANG Feng
    2023, 40(12): 1637-1643. DOI: 10.13748/j.cnki.issn1007-7693.20230385
    Abstract PDF
    Research Progress of PARP Inhibitors in Tumor Therapy
    SHEN Minmin, XU Wei, ZHANG Bo, YE Libing, LIN Nengming
    2023, 40(12): 1644-1651. DOI: 10.13748/j.cnki.issn1007-7693.20230687
    Abstract PDF
    Research Progress of anlotinib’s drug resistance and sensitivity
    XIA Zhouqi, WANG Rui, WU Jiheng, NI Shaoqing
    2023, 40(12): 1652-1657. DOI: 10.13748/j.cnki.issn1007-7693.20224042
    Abstract PDF
    Basic and Translational Research on Antitumor Drugs Promotes Clinical Therapy
    XU Aixiao, SHAO Xuejing, YING Meidan, YANG Bo
    2023, 40(12): 1658-1661. DOI: 10.13748/j.cnki.issn1007-7693.20231449
    Abstract PDF
    Therapeutic Effects of Targeted Intervention of SETDB1 in Acute Myeloid Leukemia
    XU Aixiao, ZHANG Jianhua, DU Wenxin, HE Qiaojun, YING Meidan, SHAO Xuejing
    2023, 40(12): 1662-1669. DOI: 10.13748/j.cnki.issn1007-7693.20230965
    Abstract PDF
    Research Progress in the Differentiation and Regulatory Mechanisms of Tumor Specific CD8+T Cell
    FANG Kun, FANG Yanfen
    2023, 40(12): 1670-1679. DOI: 10.13748/j.cnki.issn1007-7693.20230852
    Abstract PDF
    Research Progress on Targeting Nuclear Liquid-liquid Phase Separation for Developing Anti-tumor Drugs
    CHEN Weihao, TAN Caiwei, ZHAO Qingwei, XIE Wei
    2023, 40(12): 1680-1686. DOI: 10.13748/j.cnki.issn1007-7693.20231485
    Abstract PDF
    Preparation and in Vitro Evaluation of Redox-responsive Nano-drug Delivery System of Poly-salicylic Acid
    FENG Xuman, ZHANG Ziyi, SHI Wei, GUO Chenxi, YANG Yaxin, LIU Zhanjun
    2023, 40(12): 1687-1693. DOI: 10.13748/j.cnki.issn1007-7693.20224120
    Abstract PDF
    Preparation and in Vitro Evaluation of Reduction-responsive Methotrexate/Hydroxycamptothecin Nanoparticles
    XU Hongting, FEI Xuanting, CHEN Ruoqiao, HU Qiaohong
    2023, 40(12): 1694-1703. DOI: 10.13748/j.cnki.issn1007-7693.20230012
    Abstract PDF
    Study on Inhibitory Effect and Mechanism of Myricanol 5-Fluorobenzyloxy Ether on Proliferation of Human Lung Adenocarcinoma Cells A549-Homo BIRC5 in Vivo
    CHEN Sisi, CHEN Xuan, REN Zeming, TONG Yeling, MEI Xiyu, DAI Guanhai
    2023, 40(12): 1704-1711. DOI: 10.13748/j.cnki.issn1007-7693.20230085
    Abstract PDF
    Synergistic Anti-tumor Activity and Mechanism of Ibrutinib Combined with BH3 Analogue ABT737
    DONG Rong, TAN Biqin, YAN Youyou, YAN Wei
    2023, 40(12): 1712-1719. DOI: 10.13748/j.cnki.issn1007-7693.20223327
    Abstract PDF
    Inhibitory Effect and Mechanism of a Novel Polycyclic Spiro-epoxy Indole Compound on Lung Cell Lines Proliferation
    ZHOU Qiaoqiao, ZHANG Bin, KUANG Zhengkun, ZHOU Shiyi, TAN Fen
    2023, 40(12): 1720-1727. DOI: 10.13748/j.cnki.issn1007-7693.20221919
    Abstract PDF
    Application and Development of Chitosan-based Delivery Systems in Tumor Photothermal Therapy
    WANG Xianglong, QIU Liyan
    2023, 40(12): 1728-1737. DOI: 10.13748/j.cnki.issn1007-7693.20230340
    Abstract PDF
    Research Progress in the Study of Small Molecule Hypoxia-activated Prodrugs and HIF-1 Inhibitors Based on Hypoxia Microenvironment
    PAN Yunlong, WANG Jing, LUO Fang, WU Dan, ZHANG Jiankang, ZHU Huajian, SHAO Jia'an
    2023, 40(12): 1738-1752. DOI: 10.13748/j.cnki.issn1007-7693.20223610
    Abstract PDF